Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuroendocrine Carcinoma, Grade 3”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Testing effectiveness (Phase 2)Study completedNCT03079440
What this trial is testing

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsNeuroendocrine CarcinomaTemozolomide+1 more
Asan Medical Center 31
Early research (Phase 1)Study completedNCT00006368
What this trial is testing

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more
Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)UnknownNCT05113355
What this trial is testing

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Who this might be right for
Neuroendocrine TumorsNeuroendocrine Tumor Grade 3Neuroendocrine Carcinoma+1 more
Peking Union Medical College Hospital 23
Early research (Phase 1)Study completedNCT00073944
What this trial is testing

BCX-1777 in Treating Patients With Refractory Cancer

Who this might be right for
Cancer
BioCryst Pharmaceuticals
Not applicableStudy completedNCT00899496
What this trial is testing

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

Who this might be right for
Cancer
Wake Forest University Health Sciences 54
Early research (Phase 1)Study completedNCT00049023
What this trial is testing

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsGastrointestinal Carcinoid TumorIslet Cell Tumor+4 more
O'Dorisio, M S 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT02713269
What this trial is testing

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

Who this might be right for
Malignant Digestive System NeoplasmMetastatic Head and Neck CarcinomaMetastatic Kidney Carcinoma+10 more
M.D. Anderson Cancer Center 60
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Testing effectiveness (Phase 2)Looking for participantsNCT04325425
What this trial is testing

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

Who this might be right for
Neuroendocrine Carcinoma
Centre Hospitalier Universitaire Dijon 218
Testing effectiveness (Phase 2)UnknownNCT04525638
What this trial is testing

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Who this might be right for
Neuroendocrine Tumours (NET)Neuroendocrine Carcinomas (NEC)
Fundación de investigación HM 30
Testing effectiveness (Phase 2)Study completedNCT03147404
What this trial is testing

Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Who this might be right for
Neuroendocrine Carcinoma, Grade 3
Samsung Medical Center 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT04471727
What this trial is testing

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

Who this might be right for
Small-Cell Lung CancerNeuroendocrine Carcinoma
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 232
Early research (Phase 1)Ended earlyNCT01769222
What this trial is testing

Ipilimumab and Local Radiation for Selected Solid Tumors

Who this might be right for
Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+31 more
Stanford University 3
Early research (Phase 1)Looking for participantsNCT06889493
What this trial is testing

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

Who this might be right for
Neuroendocrine CarcinomaNeuroendocrine Tumors
Peter Hosein, MD 36
Not applicableWithdrawnNCT00378781
What this trial is testing

Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

Who this might be right for
Cancer
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT00019019
What this trial is testing

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerKidney Cancer+6 more
National Institutes of Health Clinical Center (CC) 70
Testing effectiveness (Phase 2)Study completedNCT02113800
What this trial is testing

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Who this might be right for
Poorly Differentiated Malignant Neuroendocrine CarcinomaNeuroendocrine Carcinoma, Grade 3Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3+2 more
AIO-Studien-gGmbH
Testing effectiveness (Phase 2)UnknownNCT00637637
What this trial is testing

External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases

Who this might be right for
Cancer
Oncology Institute of Southern Switzerland 60
Testing effectiveness (Phase 2)WithdrawnNCT02763761
What this trial is testing

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

Who this might be right for
Renal Cell CarcinomaMelanomaLung Cancer
Bristol-Myers Squibb
Load More Results
40